DISCUSS ALL PROS AND CONS WITH YOUR MEDICAL PROFESSIONALS.
The following list describes treatments that are among the ones most regularly reported about Cold Agglutinin Disease and by the CAD patients who visit our website. This is not intended to be a comprehensive or all-inclusive list, and it may not be appropriate for your individual situation. It is intended simply as a guide for reference and discussion. Please be aware that all treatments, including blood transfusions, can have side effects, some known and others yet to be discovered.
Clinical Trial Information:
ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the CAD Foundation.
U.S. Food and Drug Administration (FDA) approved Enjaymo (sutimlimab-jome), a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).
Enjaymo is the first and only approved treatment in CAD and works by inhibiting the destruction of red blood cells (hemolysis) and helps address a serious unmet need for people living with this rare blood disorder.
Click Here For Enjaymo Treatment Information
Rituximab (aka Rituxan) is a drug given by IV infusion which in recent years has been found effective in treating CAD, and in some cases it is administered in combination with other drugs . It is also used in treating patients with Non-Hodgkins Lymphoma and other blood cancers.